Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, Gubra raised full-year guidance, SynAct Pharma completed dosing in a phase 2 study, and Scandion Oncology will soon present data from their PANTAX trial at the ESMO Congress 2023. Furthermore, muliple companies also released earnings.
The past week was full of interesting news with 11 of the 20 listed, Danish biotech companies published news. 9 of the 20 companies had a positive development in their share price for the week and 8 companies have had a positive share price performance year to date. Fluoguide overtook Saniona as the best performing stock year-to-date.
Company news the past week
Ascendis Pharma
No news the past week
Interview with Biosergen (in Danish) (Link)
Biosergen is currently raising money via series TO2 warrants and the subscription period ends on August 25 (Link)
Biosergen AB: Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management (Link)
Cessatech
Cessatech secures DKK 5 million loan facility agreement to support the US launch of its lead program CT001 (Link)
No news the past week
No news the past week
Evaxion Biotech
Evaxion Announces Business Update and Second Quarter 2023 Financial Results (Link)
Expres2ion
ExpreS2ion announced financial results for the second quarter 2023 (Link)
Fluoguide
No news the past week
Genmab
Capital Increase in Genmab as a Result of Employee Warrant Exercise (Link)
Gubra
Gubra raises financial guidance for full-year 2023 (Link)
Initiator Pharma
No news the past week
IO Biotech
No news the past week
Pila Pharma
No news the past week
Saniona
Saniona reduces and extends loan (Link)
Saniona executes the set-off issue to Formue Nord (Link)
Scandion Oncology
Data from PANTAX trial to be presented at ESMO Congress 2023 (Link)
SynAct Pharma
SynAct Pharma completes dosing in part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA) (Link)
ViroGates
ViroGates announces its half-year report for H1, 2023: Revenue is still negatively affected by lower-than-expected sales to clinical routine customers (Link)
Zealand Pharma
Zealand Pharma Announces Financial Results for the First Half of 2023 (Link)
Y-mAbs Therapeutics
No news the past week
2cureX
No news the past week
SELECTED CASES
SHARE PRICE DEVELOPMENTS
On average, the Danish biotech stocks delivered a negative share price performance last week of -2.2%. Gubra became the best performing stock with an 10% after raising the financial guidance for full-yaer 2023. Zealand Pharma also rose 10% after release of their financial report. The best stocks year-to-date include Curasight, Fluoguide, and Saniona after soaring 80-142% even though Saniona took a big hit last week following loan news. Overall the Danish biotech stocks are in negative terrotory this year with a year-to-date return of -0,2% driven by the few companies delivering a positive return.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months
